

Dr ZAHRA MADJD, MD PhD

PERSONAL DETAILS

Surname: MADJD

First Name: Zahra (Maryam)

Sex: Female

Telephone/ Fax (work): 0044 21 88602209

Telephone (home): 0044 21 22679994

Telephone (mobile): 09125985608, 09122115440

E-mail: Zahra.madjd@yahoo.com

Academic Attainments

Dates	Description of qualification	Place obtained
1987	Diploma	Tehran, Iran
1988 -1996	Doctorate in Medicine	Tehran, Iran
1996- 2000	General Practitioner	Tehran, Iran
2000-2001	modules in MSc Oncology	University of Nottingham
2001- 2004	PhD Oncology (Immunopathology) Supervisors: Prof James Carmicheal (Professor of Oncology) Professor LG Durrant (Professor of Immunology) Professor Ian O Ellis (Professor of Cancer Pathology)	University of Nottingham, City Hospital, Dep. Clinical Oncology/ Dep. Of Pathology
2004 - 2005	Post-doctoral Research Fellow Professor LG Durrant (Professor of Immunology)	University of Nottingham, City Hospital, Dep. Clinical Oncology
2006	Career Development Fellowship, Post doctorate Scientist Director: Professor Sir John Walker (Nobel Prize Winner ,1997) , Professor Sheila Bingham	University of Cambridge, Addenbrock's Hospital, MRC, Human Nutrition Unit
From august 2006	Assistant Professor of Immunopathology	Dep Pathology, Faculty of Medicine, Iran University of Medical Sciences

Previous appointments

Date From	To	No. of months	Grade and Specialty	Place held
2006	2009	Not finished, Leave to Iran (contract for 3 years)	Career Development Fellowship, Post doctorate Scientist	University of Cambridge, Addenbrock's Hospital, MRC, Human Nutrition Unit
2004	2005	15 months	Post-doctoral Research Fellow	University of Nottingham, City Hospital, Dep. Of Clinical Oncology
1999		6 month	Ministry of health and medical sciences, Expert	Tehran, Iran
1996	1999	42 months	General Practitioner	Shahid Beheshti University of Medical Sciences ,Tehran, Iran

Details of recent research, employments and activities

Assistant Professor of Immunopathology, Iran University of Medical Sciences, Department of pathology, Faculty of Medicine

- Co-editor of **Iranian Journal of Cancer Prevention**, Shahid Beheshti University of Medical Sciences, Shohada tajrish
- **Scientific Referee of 8th Congress of Iranian Society of Pathology, Oct 2006**, Tehran, Iran
- Member of **Scientific Committee of 9th Congress of Iranian Society of Pathology, Nov 2007**, Tehran, Iran

Research Activities:

1. Member of **Cancer Research Centre**, Shahid Beheshti University of Medical Sciences, Shohada tajrish
2. Member of **Oncopathology Research Centre**, Iran university of Medical Sciences
3. Activity in **Cellular Molecular Research Centre**, Iran university of Medical Sciences
4. set up of Immunohistochemistry lab in the Department of Pathology (In process)

Accepted proposals:

- 1) The role of Bcl 2 as biomarker of apoptosis resistance and its relation with marker of breast cancer stem Cells (CD44) and ER/PR in human.
- 2) Correlation of CD44, marker of breast cancer stem cells, with ER, PR and Erb2 to find a new therapeutic target
- 3) Expression of human embryonic stem cell genes *OCT4*, *NANOG* in breast and thyroid carcinoma compared to testicular carcinoma
- 4) Relationship between Breast Cancer and Breast Abscess (Submitted)

Education:

Teaching:

Pathology lectures: for Pathology Residents, Medical Students, Msc Immunology, MPH students, Bsc midwifery, Bsc Public health (Iran University of Medical Sciences), Msc Immunology (Shahid Beheshti University)

Immunology Lectures: for PhD Immunology, MSc Immunology, MSc Parasitology (Iran University), Medical students, Pharmacology students, Dentist students (Shahid Beheshti University)

Lectures and Oral presentations in this period (since Sep 2006):

1. Lectures in Pathology CME, Iran University of Medical Sciences, May 2007
2. Breast Cancer congress, Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Feb 2007.
3. CD59 as an independent indicator of poor prognosis in breast carcinomas , a tissue microarray study of 520 patients, presented in 8thCongress of Iranian Society of Pathology , 2-4 Nov 2006, Tehran
4. Teaching of Workshop (Immunohistochemistry and Tissue microarray) 8thCongress of Iranian Society of Pathology, 2-4 Nov 2006, Tehran
5. Teaching of Workshop (Occupational Cancers), 29 Oct 2006
6. Second Congress of Breast, 9-10 Nov, Tehran
7. International Royan Congress, Sep 2006, Tehran

Career Development Fellowship, Post doctorate Scientist, University of Cambridge, Addenbrock's Hospital, MRC Dunn Human Nutrition Unit, Diet and Cancer research group
Outline of study: DNA adducts, differences in gene expression and DNA damage and histochemistry of tumour samples

Post-doctoral Research Fellow

University of Nottingham, City Hospital, Dep. Of Clinical Oncology

Outline of study: Study of immune-surveillance pathway in Breast tumours

Duties:

1. Identifying immunology markers in tumours particularly breast and colorectal tumours to help stratify patients for optimal therapy.
2. Supervising MSC student to study IFN γ R1, stat1, TRAIL-R2, P21 and P27 on breast tumours. This student was awarded distinction for his project.
3. Study of complement regulatory proteins and MHC class I, MICA molecules, INFR1 and STAT pathway on colorectal Tissue microarray using immunohistochemistry in collaboration with clinical research fellow from Dep of surgery.
4. Study of Bcl2, P53 and p62 molecules on breast tissue microarray using immunohistochemistry in collaboration with clinical research fellow from Dep of Gynaecology.
5. Training senior staff, research fellows, PhD and MSc students the related techniques
6. Preparation of draft scientific papers and reports to founding sources
7. Preparation of draft papers for publication or presentation in the conferences
8. Presentations to group
9. Regular attendance in the weekly immunology meetings.

Honours or Prizes

- EACR-18 (European Association of Cancer Research) award, July 2004, Innsbruck, Austria.
- BACR (British Association of Cancer Research) award at the ECCO13 meeting, October 2005, Paris. 800 pounds

Memberships

1. BACR (British Association for Cancer Research), subscription
2. EACR (European Association for Cancer Research), subscription
3. AAAS (American Association for the Advancement of Science)

RESEARCH EXPERIENCE

A) MD dissertation:

Supervisor: Professor Freidoon Azizi

“Characteristics of thyroid disorders before and after iodized salt consumption in Tehran during 1993-5”.

This study was conducted among patients with thyroid disorders referred to a major Thyroid Referral Centre consisting a population of 12000 patients, that was presented in oral session in 4th International Congress of Endocrine Disorders, Tehran Nov 1996.

B) Description of PhD projects:

Part One: Study of expression of complement regulatory proteins (CIPs) in solid tumours. These antigens (CIPs) are targets for monoclonal antibody therapy (mab), as over-expression of CIPs limits the effectiveness of mab therapy.

Outcome of project: I have examined a number of complement regulatory proteins CD59, CD55 and CD46 on over 600 breast tumours using tissue microarray technology. The results showed that poor prognosis breast tumours lost CD59 and CD55 but still had CD46 to protect them from complement attack. The results of these studies have successfully been published in prestigious Journals. (CD59; J Pathology.

August 2003) (CD55, Clinical Cancer Research. April 2004) (CD46; Cancer Immunology Immunotherapy. Sep 2004).

Part 2: Study of the expression of MHC class I molecule and the stress-related molecule MICA and natural killer cells (CD56+) on the same series of breast tissue arrays as above.

Outcome of project: These studies unexpectedly showed up-regulation of HLA ABC and MICA in poor prognosis breast tumours. Several abstracts on these studies have been published and three manuscripts are in preparation.

DETAILS OF RESEARCH EXPERIENCE:

1. Tissue culture:

Tissue culture of a variety of cell lines derived from solid tumours including;

- Colorectal cell lines (Colo205, C170, R1D9)
- Breast cell lines (MCF-7, MDA 231, MDA 435, ZR75, and T47D)
- Ovarian cell lines (OAW28, PA1), gastric (MKN45), squamous (A 431), bladder (T24) and osteosarcoma (791T)
- Other cells such as promyelocytic (HL60), monocytic (U937) and promyeloblastic (KG1a)
- HUVEC isolation and culture of HUVEC
- Isolation of activated PBMCs (Peripheral Blood Mononuclear cells) onto histopaque
- Isolation of T cells and T cell culture
- Culture of hybridoma cells

2. Producing monoclonal antibody from hybridoma:

- To overcome the lack of commercial antibodies for complement regulatory proteins, new monoclonal antibodies (mabs) to CRPs CD55 and CD46 developed that worked on denature proteins and paraffin tissue sections. The specificity of these mabs then has been confirmed by western blot and blocking with specific peptide. The methodology included;
- Design of specific peptide using BLAST search
- Immunisation of mice with specific peptide based on protocol
- Fusion of myeloma cell line NSO with immunised mouse splenocytes
- Culture of Hybridoma and screening by ELISA
- Cloning, Isotype determination and purification of antibody.

3. ELISA:

- Using ELISA to look at expression of complement regulatory proteins (CRPs) on a variety of tumour cell lines including breast (MCF-7, MDA231, MDA435, ZR75, T 47D), colorectal (Colo205, C170, R1D9), gastric (MKN45), bladder (T24), squamous (A431), osteosarcoma (791T) and ovarian (OAW28, PA1)
- HUVEC.
- Screening of hybridoma
- Screening of peptide

4. FACS (Flow cytometry):

- Study of expression of complement regulatory proteins (CRPs), MHC class I on different tumour cell lines including:
- Bladder and breast cell lines
- T cells
- dendritic cells
- Leukaemia cell lines; promyelocytic (HL60), promyeloblastic (KG1a) and monocytic (U937) were assessed by FACS analysis

5. SDS polyacrylamide gel electrophoresis (SDS-PAGE) and Western-Blotting:

To confirm specificity of monoclonal antibodies anti-CD46, anti-CD55 and MICA, which produced from hybridoma, western blot was performed.

6. RT-PCR

To examine the relative mRNA expression of the complement (C) regulatory proteins

7. Immunohistochemistry:

I am fully skilled with immunohistochemistry methods for staining of tumour samples either paraffin embedded sections or frozen sections, titration of antibodies, scoring (semi- quantitative or image analysis), analysis and interpretation of the data (SPSS and Microsoft Excel). I have also knowledge of immunohistochemistry of DNA adducts and gene expression.

I have experience of teaching this method for PhD and MSc students, research fellows and senior staff during my PhD and post doc.

8. Having basic knowledge of experiments related to cellular immunology, peripheral tolerance and autoimmunity

4) Histopathology:

1. I have been involved in Histopathology training and research acting as a Clinical observer which comprises a broad range of Histopathology activities.
2. Experience of most aspects of routine Histopathology service work in Nottingham City Hospital, as clinical attachment, under supervision of consultants.
3. Principles of surgical pathology, surgical cut up techniques and basic reporting of relatively simple specimens
4. Basic principles of gynaecological and non-gynaecological cytology screening and diagnostic programmes.
5. Observation of autopsy pathology (post-mortem examinations).
6. Attending in routine SHO training courses in Trent region (Leicester, Nottingham MRCPATH teaching course)
7. Working with binuclear microscope

Other Histopathology experiences

1. Familiar with preparing tissue microarrays and selecting the most representative area of a tumour
2. Fully skilled with performing immunohistochemistry and expert in the staining of paraffin embedded and frozen sections as well as developing techniques including assessment of and titration of antibodies.
3. Expert in different scoring systems for immunohistochemistry (semi- quantitative or image analysis) and interpretation and analysis of data by different statistical packages.
4. Teaching of above methods to clinical research fellows, senior technician, PhD and MSC students in Department of clinical oncology, Nottingham City Hospital.
5. Initiation of immunohistochemistry group in department of clinical oncology.

PUBLICATIONS

Published papers

1. Loss of CD59 expression in breast tumours correlates with poor survival. **Madjd Z**, Pinder S E, Paish C, Ellis IO, Carmichael J, Durrant L G. J Pathology (2005 IF: **6.213**) , 2003, 200: 633-639.
2. Loss of CD55 is associated with aggressive breast tumours. **Madjd Z**, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. Clinical Cancer Research (2005 IF: **5.715**), 2004, 10: 2797-2803
3. Do poor prognosis breast tumours express membrane cofactor proteins (CD46)? **Madjd Z**, Durrant LG, Pinder SE, Ellis IO, Ronan J, Rushmere NK and Spendlove. Cancer Immunology Immunotherapy (2005 IF: **4.086**), 2005 Feb;54(2):149-56
4. Total loss of MHC class I molecules is an independent indicator of good prognosis in breast cancers. **Madjd Z**, Pinder SE, Spendlove I, Ellis IO, and Durrant LG. International J Cancer (2005 IF: **4.700**) . 2005 Nov 1; 117(2): 248-55.
5. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC Class I expression correlates with a poor prognosis in early stage patients. Watson NFS, Ramage J, **Madjd Z**, Spendlove I, Ellis IO, Scholefield J, Durrant LG. Int J Cancer (2005 IF: **4.700**) . 2006 Jan 1; 118(1): 6-10.
6. Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients. Watson NFS, **Madjd Z**, Ellis IO, Scholefield J, Spendlove I. Durrant LG. World J Surg Oncology (2005 IF: **1.56**). 2005 Jul 19; 3:47.
7. Expression of the Membrane Complement Regulatory Protein CD59 (Protectin) is Associated with Reduced Survival in Colorectal Cancer patients. Watson NFS, Durrant LG, **Madjd Z**, Ellis IO, Scholefield J, and Spendlove I. Cancer Immunology Immunotherapy (2005 IF: **4.086**) . 2005 Sep 3;1-8
8. Over-expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. **Madjd Z**, Parsons T, Watson NFS, Spendlove I, Ellis IO and Durrant LG. Breast Cancer Research. (2005 IF: **4.03**); 7(5):R780-7. 2005 Jul 28.
9. Expression of the stress related protein MICA is an independent indicator of good prognosis in colorectal cancer patients. Watson NFS, Spendlove I, **Madjd Z**, Moss R, Green A, Ellis IO, Durrant LG, Scholefield JH. International J Cancer (2005 IF: **4.700**). 2006 Mar 15; 118(6):1445-52.
10. Cytoplasmic expression p27^{KIP-1} is associated with a favourable prognosis in colorectal cancer patients. NFS Watson, LG Durrant, JH Scholefield, **Z Madjd**, D Scrimgeour, I Spendlove, IO Ellis, PM Patel. World J Gastroenterology. 2006Oct 21,12(39).
11. The p53 Positive Bcl-2 Negative Phenotype is an independent marker of prognosis in breast cancer. Phil Rolland, Ian Spendlove, **Zahra Madjd**, Emad A Rakha, ,Patel Poulam, Ian O. Ellis, Lindy Durrant. International J Cancer (2005 IF: **4.700**), 22 Dec 2006 .
12. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Rolland P, **Madjd Z**, Durrant L, Ellis IO, Layfield R, Spendlove I. Endocrine Related Cancer(2005 IF: 6). 2007 Mar;14(1):73-80.

13. Up-regulation of MICA on high-grade breast carcinomas. **Madjd Z**, Pinder SE, Spendlove I, Watson NFS, Moss R, Bevan S, Durrant LG. accepted Cancer immunity, 2007

Accepted papers

14. The prognostic significance of membrane bound complement regulatory protein expression in ovarian cancer. Rolland P, Deen S, **Madjd Z**, Scott Ian, Liu D, Durrant LG, Spendlove I. J Pathology 2006

In Preparation

15. Co-expression of P27 kip1/p21 is an independent indicator of good prognosis in lymph node positive breast carcinomas. **Zahra Madjd**, Ahmad Al-Attar, Nicholas FS Watson, Ian Spendlove, Duncan Scrimgeour, Ian Ellis and Lindy G Durrant.
16. STAT1 expression is an independent indicator of prognosis in lymph node positive breast carcinomas. **Zahra Madjd**, Ahmad Al-Attar, Nicholas FS Watson, Ian Spendlove, Duncan Scrimgeour, Ian Ellis and Lindy G Durrant

Referee of Journal, 2005

I have recently **reviewed** the following manuscript: Increased values of tumor marker Ca 15-3 and the removal of the interpectoral (Rotter's) lymph nodes may be beneficial for breast cancer patients with axillary nodal involvement for the Journal of **Neoplasia**.

Referee of Annual Pathology Congress, Sep 2006, Tehran, Iran

ABSTRACTS AND CONFERENCE PROCEEDINGS

1. **Madjd Z**, Asadi-Lari M, Azizi F. Characteristics of thyroid disorders before and after iodized salt consumption. Proceeding of 4th International Congress on Endocrine Disorders, Nov 1996
2. **Madjd Z**, Pinder S, Ellis I O, Carmichael J, Durrant LG. CD59 and CD55 as independent indicator of poor prognosis in breast cancer patients. **British J of Cancer. 86, 2002.**
3. **Madjd Z**, Spendlove I, Pinder SE, Moss R, Bradley R, Durrant L. Expression of complement regulatory proteins CD55 and CD59 on breast cancer. **Clinical Cancer Research, 2003 proceeding of the AACR.**
4. **Madjd Z**, Pinder SE, Spendlove I, and Durrant LG. Expression of CD55 (Decay Accelerating Factor) in breast carcinomas and its prognostic significance. **Immunology Letters. 2003, 87, P:208** (Abstracts of the 15th European Immunology Congress (EFIS 2003).
5. **Madjd Z**, Pinder SE, Spendlove I and Durrant LG. Unexpectedly loss of CD55 and CD59 is associated with aggressive breast tumours. **FASEB Journal, Vol.17, Issue 7, 2003.** (2003 Proceeding of the AAI).
6. **Madjd Z**, Pinder SE, Spendlove I, Durrant LG. Prognostic value of complement regulatory proteins CD55 and CD59 in breast cancer. **British J Cancer. Supplement July, 2003.**
7. **Madjd Z**, Pinder SE, Spendlove I, Durrant LG. Which complement regulatory proteins could be a good target for a breast cancer vaccine? **European J Cancer. Vol 1 No 5, Sep 2003.**
8. **Madjd Z**, Bevin S, Spendlove I, Moss R, Durrant LG. Expression of MHC class I-related molecule MICA in breast carcinomas and its prognostic significance. **Immunology. Supplement. December 2003.**
9. **Madjd Z**, Spendlove I, Pinder SE, Rushmere NK, Morgan BP and Lindy G Durrant. Expression of membrane cofactor protein (CD46) on breast tumours. **Clinical Cancer Research, 2004 proceeding of the AACR.**
10. **Madjd Z**, Pinder SE, Spendlove I, Moss R, Bevin S, Durrant LG. Up-regulation of stress inducible MICA on high-grade breast carcinomas. **Supplement Cancer Detection and Prevention Strategy, Jan 2004.**
11. **Madjd Z**, Pinder S E, Spendlove I, Ellis I O, and Durrant L G. Unexpected up regulation of MHC class I molecules in poor prognosis breast cancer. **British J Cancer. Supplement June 2004.** [presented **orally** in BCRM, 2004, Manchester]

12. **Madjd Z**, Pinder S E, Ian Spendlove, John Ronan and Lindy G Durrant. Loss of MHC class I molecules in breast tumours results in susceptibility to natural killer cell activation. **European J Cancer, Supplement, July 2004.**
13. **Madjd Z**, Pinder S E, Spendlove I, Ellis I O, and Durrant LG. Loss of HLA class I is associated with good prognosis in breast cancer patients. **Proceeding of BIR, Nov 2004.** [presented orally in Prognostic Testing in Cancer, BIR, London, Nov 2004]
14. **Madjd Z**, Pinder S E, Spendlove I, Ellis I O, and Durrant LG. Loss of MHC Class I is an independent indicator of good prognosis in breast Cancer. **Proceeding of AACR, 2005.**
15. **Madjd Z**, Spendlove I, Ellis IO, Parsons T, and Durrant LG. Prognostic significance of SC101, a monoclonal Antibody against Lewis^{y/b} in breast tumours. **Proceeding of AACR, 2005.**
16. **Madjd Z**, Pinder S E, Spendlove I, Ellis IO, and Durrant LG. Prognostic significance of membrane cofactor protein (CD46) on breast tumours. **Immunology 2004, 113 (S1), British Society for Immunology, Harrogate 2004 .**
17. Watson NFS, Scholefield J, **Madjd Z**, Green A, Moss R, Spendlove, Ellis IO, Durrant LG. Prognostic value of MICA expression in colorectal carcinoma. **Immunology 2004; 113: (s1) late supplement. British Society for Immunology, Harrogate 2004 .**
18. NFS Watson, JH Scholefield, **Z Madjd**, A Green, R Moss, I Spendlove, IO Ellis and LG Durrant. Prognostic value of MICA expression in colorectal carcinoma. The Ninety-Ninth Annual General Meeting of the Physicians of Great Britain and Ireland, **Nottingham, April 2005 .**
19. NFS Watson, I Spendlove, **Z Madjd**, R Moss, A Green, IO Ellis, LG Durrant, JH Scholefield. The prognostic significance of MICA expression in colorectal cancer: An immunohistochemical study using prognostic tissue microarrays. The association of coloproctology of Great Britain and Ireland, The Royal Dublin Society, **5-7 July 2005 (oral).**
20. **Zahra Madjd**, Ahmad Al-Attar, Nicholas FS Watson Ian Spendlove, Ian Ellis and Lindy G Durrant. High expression of SC101 antibody is associated with decreased survival in lymph node negative carcinomas. ncri. October 2005. Birmingham
21. **Zahra Madjd**, Ahmad Al-Attar, Nicholas FS Watson Ian Spendlove, Ian Ellis and Lindy G Durrant. Stat1 expression is an independent indicator of prognosis in lymph node positive carcinomas. ncri. October 2005. Birmingham
22. **Zahra Madjd**, Ahmad Al-Attar, Nicholas FS Watson Ian Spendlove, Ian Ellis and Lindy G Durrant. Prognostic significant of IFN γ receptor (IFNGR1) in breast carcinomas. ECCO 13. Paris NOV 2005
23. Ahmad Al-Attar, **Zahra Madjd**, Nicholas FS Watson, Ian Spendlove, Duncan Scrimgeour, Ian Ellis and Lindy G Durrant. Co-expression of P27 kip1/p21 is an independent indicator of good prognosis in lymph node positive breast carcinomas. ECCO13. Paris NOV 2005
24. NFS Watson, **Z Madjd**, D Scrimgeour, A Al-Attar, I Spendlove, IO Ellis, JH Scholefield and LG Durrant. Cytoplasmic p27^{KIP-1} expression is an indicator of good prognosis in colorectal carcinomas. ECCO13. Paris NOV 2005
25. NFS Watson, R Moss, **Z Madjd**, I Spendlove, JH Scholefield and LG Durrant. Prognostic impact of Stat1 expression in colorectal cancer patients. **Immunology 2005, British Society for Immunology, Harrogate, Dec 2005**
26. **Madjd Z**, Hashemi F, Kadivar M, Rakhshani N, Asadi Lari. Prevalence of cancer stem cells and its association with ER, PR and Erb2 in breast cancer patients. European Conference on Cancer and Ageing Warsaw, Poland, October 4-6, 2007
27. **Madjd Z**, Zare Mehrjerdi A, Sharifi A, Molanaei S, Zohoorian S, Sadeghipour A, Asadi Lari M. **Can breast cancer stem cells resist apoptosis through the regulation of Bcl2? An immunohistochemistry study of 200 breast tumours. Iranian Congress of Pathology. Nov 2007.**
28. **Madjd Z**, Durrant LG, and Pinder SE. Can complement regulatory proteins use as a target for cancer vaccine in breast cancer patients? APCC, Dec 2007.

TEACHING EXPERIENCE

- 1) Supervision of clinical research fellow (surgery) for study of prognostic factors in colorectal tissue microarray.
- 2) Supervision of clinical research fellow (gynaecology) for study of prognostic factor in breast tissue array.
- 3) Supervision of MSc student (oncology) for making breast tissue array and study of prognostic factors in breast tumours.

- 4) Demonstration of ECG in men for BioMed Science students, University of Nottingham: 2004
- 5) Demonstration of for pharmacy students, University of Nottingham: 2004
- 6) Supervision of undergraduate students for lab skills in the Department of Clinical Oncology during PhD course: 2001-2004
- 7) Short courses for administrative and health professionals in the Department of School Health: 1999
- 8) Running workshops and short courses for health allies in health centres
- 9) Training junior doctors (externs) and medical students at various wards during internship: 1994-1996

COURSES

1. Multi Disciplinary Course on Breast Disease, Nottingham Breast Institute 21-23 November 2005.

2. Core of Knowledge (laser/IPL therapy), Laser Training & Education Centre, 5th Oct 2005

3. Teaching Course

- Leicester/ Nottingham MRCPATH Teaching Course (Sep-Dec 2004)
- Prognostic Testing in Cancer, BIR, London, 3 Nov 2004 (5 CPD Credits)

4. Summer school

Cancer Research at Nottingham Summer School and European Association for Cancer Research Symposium, Nottingham, 23-26 July, 2004 (19 CPD Credits)

5. 18th EACR meeting, July 2004, Innsbruck, Austria (24 credit points).

6. Courses in MSc Oncology (University of Nottingham), 2001-2002

These modules have formally been recognised as a course.

1. Diagnostic Pathology of Cancer (15 credits)
2. Techniques in Cellular and Molecular Biology (15 credits)
3. Tumour physiology and immunology (10 credits)

7. Intensive course in English and study Skills

Full-time English Language and Study Skills Course at Centre for English Language Education (CELE), University of Nottingham, for 3 months, September 2000-December 2000.

8. Short term courses (University of Nottingham): 2001-2003

- Introduction to Library Skills, Nottingham Oct 2001
- Study Design/ Experimental Critique, Nottingham Nov 2001
- Statistics, Nottingham, Dec 2001
- Critical Analysis, Nottingham Jan 2002
- Scientific writing, Nottingham, Feb 2002
- Preparing Poster Presentation, Nottingham, March 2002
- PowerPoint for Presentation, Apr 2002
- Scientific Abstract, June 2002
- Excel Intermediate, Nottingham, June 2002
- Further presentation skills, Nov 2001
- Building a bibliography, July 2002
- An introduction to SPSS, May 2002
- Getting More from Microsoft office Applications word, Excel and power point, Nov 2001.
- Getting started with research Design and Statistics, Jan 2002
- Working with Radioactive Substances, March 2002
- Interview workshop, August 2002
- Using Word for Long Documents, December 2002

CONFERENCES

- British Association of Cancer Research, July 2001, Leeds
- British Association of Cancer Research, July 2002, Glasgow
- Progress in vaccine against Cancer (PIVAC), July 2002, Nottingham
- American Association of Cancer Research, March 2003.
- 15th European Immunology Congress (EFIS), 2003.
- American Association of Immunology (AAI), May 2003
- British Association of Cancer Research (BACR), July 2003, Bournemouth
- Federation of European Cancer Societies (FECS), ECCO 12, September 2003, Copenhagen.
- British Society of Immunology (BSI) December 2003, Harrogate.
- American Association of Cancer Research (AACR) March 2004, Orlando
- Cancer Detection and Prevention Strategy, Jan 2004, Nice, France.
- British Cancer Research Meeting (BCRM), Manchester, June 2004.
- European Association of Cancer Research (EACR), July 2004, Innsbruck, Austria.
- NCRI (National Cancer Research Institute), Birmingham, Oct 2005.
- ECCO13 (European Cancer Conference), Paris, Nov 2005.
- International Royan Congress, Sep 2006, Tehran